Skip to content
SanegeneBio
-
SanegeneBio signs USD1.5B licensing agreement with Genentech for its RNAi therapy platform
The deal centers on one of SanegeneBio’s innovative RNAi programs and grants Genentech exclusive worldwide rights to develop and bring the treatment to market.